Table 4.
Dosing by cohort for the cetuximab-IRDye800CW and the panitumumab-IRDye800CW trials.
| Cohort 1 | Cohort 2 | Cohort 3 | ||||
|---|---|---|---|---|---|---|
| Cetux800 | Pan800 | Cetux800 | Pan800 | Cetux800 | Pan800 | |
| Dosage | 2.5 | 0.06 | 25 | 0.5 | 62.5 | 1 |
| (% of Therapeutic Dose) | mg/m2
(1%) |
mg/kg (1%) |
mg/m2
(10%) |
mg/kg (8%) |
mg/m2 (25%) |
mg/kg (17%) |
|
Average Dose Received (mg ± SD) |
5.2 ± 0.7 | 4.7 ± 0.7 | 48.8 ± 5.2 | 39.2 ± 6.9 | 130.4 ± 26.9 | 69.1 ± 12.3 |
| Plasma Volume (mg ± SEM) | ||||||
| 3 hours post-infusion | 5.4 ± 0.7 | 0.7 ± 0.1 | 50.0 ± 3.5 | 43.1 ± 3.1 | 94.7 ± 23.0 | 69.0 ± 5.8 |
| 24 hours post-infusion | 2.8 ± 0.4 | 0.4 ± 0.1 | 27.3 ± 5.3 | 28.4 ± 3.7 | 68.1 ± 14.7 | 28.9 ± 4.2 |